Who
Corrine Savill
Chief Business Officer
Company insider
Files Form 4 as: Chief Business Officer, Cullinan Therapeutics.
In numbers
- Trades disclosed
- 28
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $2.5M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 11 Feb 2022
- Last trade
- 18 Feb 2026
- Last filed
- 19 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Feb 2026filed 19 Feb 2026 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 18 Feb 2026filed 19 Feb 2026 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 19 Feb 2025filed 21 Feb 2025 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 19 Feb 2025filed 21 Feb 2025 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 22 Feb 2024filed 23 Feb 2024 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 22 Feb 2024filed 23 Feb 2024 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 1 Feb 2024filed 2 Feb 2024 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —40,000 at $0.00 | filing |
| 1 Feb 2024filed 2 Feb 2024 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Code M | $172K40,000 at $4.30 | filing |
| 1 Feb 2024filed 2 Feb 2024 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $647K40,000 at $16.18 | filing |
| 29 Jan 2024filed 30 Jan 2024 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —13,997 at $0.00 | filing |
| 29 Jan 2024filed 30 Jan 2024 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —26,003 at $0.00 | filing |
| 29 Jan 2024filed 30 Jan 2024 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Code M | $172K40,000 at $4.30 | filing |
| 29 Jan 2024filed 30 Jan 2024 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $564K40,000 at $14.09 | filing |
| 23 Jan 2024filed 24 Jan 2024 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —21,316 at $0.00 | filing |
| 23 Jan 2024filed 24 Jan 2024 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Code M | $92K21,316 at $4.30 | filing |
| 23 Jan 2024filed 24 Jan 2024 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $266K21,316 at $12.46 | filing |
| 22 Jan 2024filed 24 Jan 2024 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —14,559 at $0.00 | filing |
| 22 Jan 2024filed 24 Jan 2024 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Code M | $63K14,559 at $4.30 | filing |
| 22 Jan 2024filed 24 Jan 2024 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $177K14,559 at $12.18 | filing |
| 22 Jan 2024filed 24 Jan 2024 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $50K4,125 at $12.02 | filing |
News
No headline names them, or the companies they trade most, lately.